We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.29%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.31B
AUM Growth
+$931M
Cap. Flow
+$3.42M
Cap. Flow %
0.05%
Top 10 Hldgs %
41.19%
Holding
233
New
22
Increased
88
Reduced
44
Closed
17

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$66M
2
CRL icon
Charles River Laboratories
CRL
+$38M
3
WVE icon
Wave Life Sciences
WVE
+$20.8M
4
ABT icon
Abbott
ABT
+$19M
5
PACB icon
Pacific Biosciences
PACB
+$17.1M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$108M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$84.7M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$53.2M
4
GILD icon
Gilead Sciences
GILD
+$35.4M
5
TDOC icon
Teladoc Health
TDOC
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Industrials 0.45%
3 Technology 0.42%
4 Communication Services 0.09%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BR icon
201
Broadridge
BR
$17.2B
$420K 0.01%
3,400
– –
CL icon
202
Colgate-Palmolive
CL
$72.6B
$420K 0.01%
6,100
– –
BKNG icon
203
Booking.com
BKNG
$138B
$411K 0.01%
5,000
– –
XLNX
204
DELISTED
Xilinx Inc
XLNX
$411K 0.01%
4,200
– –
VRSN icon
205
VeriSign
VRSN
$25.5B
$405K 0.01%
2,100
– –
HSIC icon
206
Henry Schein
HSIC
$9.74B
$397K 0.01%
5,948
-57,627
-91% -$3.81M
SCI icon
207
Service Corp International
SCI
$11.4B
$391K 0.01%
+8,500
New +$383K
STZ icon
208
Constellation Brands
STZ
$22.2B
$391K 0.01%
+2,059
New +$389K
SBUX icon
209
Starbucks
SBUX
$118B
$381K 0.01%
4,334
– –
VRSK icon
210
Verisk Analytics
VRSK
$26.4B
$372K 0.01%
2,489
– –
AZPN
211
DELISTED
ASPEN TECHNOLOGY INC
AZPN
$363K 0.01%
3,000
– –
KOS icon
212
Kosmos Energy
KOS
$1.56B
$342K 0.01%
60,000
– –
BLKB icon
213
Blackbaud
BLKB
$1.5B
$327K 0.01%
4,107
– –
BIIB icon
214
Biogen
BIIB
$29.9B
$148K ﹤0.01%
500
-31,850
-98% -$8.84M
CVET
215
DELISTED
Covetrus, Inc. Common Stock
CVET
$20K ﹤0.01%
1,520
– –
BIIB icon
216
CALL
Biogen
BIIB
$29.9B
$8K ﹤0.01%
+160
New +$44.4K
ASND icon
217
Ascendis Pharma A/S
ASND
$16.7B
– –
-13,600
Closed -$1.31M
JNJ icon
218
Johnson & Johnson
JNJ
$634B
– –
-10,000
Closed -$1.29M
KEX icon
219
Kirby Corp
KEX
$7.95B
– –
-5,900
Closed -$485K
LABD icon
220
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$65.4M
– –
-275
Closed -$1.39M
LIN icon
221
Linde
LIN
$237B
– –
-1,848
Closed -$358K
MCHP icon
222
Microchip Technology
MCHP
$42.8B
– –
-10,000
Closed -$465K
MTLS
223
Materialise
MTLS
$379M
– –
-240,770
Closed -$4.45M
VNE
224
DELISTED
Veoneer, Inc.
VNE
– –
-29,700
Closed -$445K
ARNA
225
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-23,517
Closed -$1.08M
6 7 8
9
10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2019 Portfolio in Review

As of Q4 2019, Bellevue Group held 233 positions worth $6.31B, up 17% from $5.38B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q4 2019 filing shows 22 new, 88 increased, 44 reduced and 17 closed positions. Its largest new stake was Molecular Templates, Inc.: 86,379 shares worth $18.1M. The largest sale was Celgene Corp, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q4 2019 buy was Molecular Templates, Inc.: 86,379 shares worth $18.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $66M increase.
  • Bellevue Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $53.2M.
  • Bellevue Group fully exited Celgene Corp in Q4 2019, selling an estimated $108M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.31B portfolio in Q4 2019.
  • Bellevue Group opened 22 new positions and closed 17 in Q4 2019.
  • Bellevue Group's portfolio value rose 17% quarter-over-quarter to $6.31B.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.